Sigachi Industries Ltd

- Sigachi Industries is currently seeking an umbrella approval for raising funds through Foreign Currency Convertible Bonds (FCCBs), which requires RBI, SEBI, and shareholder approvals. - The company is not planning to raise all the funds immediately but will tap the FCCB route as needed for growth. - The FCCBs would carry a coupon rate and are not purely equity dilution at this moment. - The management emphasizes careful cost-benefit analysis before any new capex, implying funding will be raised only if it benefits the company. - There is no mention of a current definitive equity fundraising; the FCCB approval is preparatory. - Promoter shareholding will increase after full payment of preferential shares; no promoter selling or dilution is planned now. - Any new fundraising will be executed through the best available options, balancing loan and equity components depending on opportunity. Thus, while immediate fundraising is not underway, the company has structured approvals and intent for future debt/equity funding as required.

- Ongoing capex includes API expansion and CCS expansion with timelines around 12 to 18 months. - New coating product capacities (PureCot and Ultramod) have commenced operations and are in sampling phase. - Plan to increase MCC capacity soon due to 50% utilization of current expanded capacity and strong demand. - Future MCC capacity expansions are likely within 2 to 3 years, driven by demand and consumption growth. - Capex also planned for setting up a manufacturing plant in the USA to reduce freight and logistics costs. - Company is seeking umbrella approval for raising funds via unsecured convertible bonds (FCCB) to support growth capex. - CCS plant project delayed due to pending pollution control board approval; progress expected once approvals are received. - Focus on incremental capex only after thorough cost-benefit analysis to ensure it supports business growth.

- Sigachi Industries expects top-line growth of approximately 30% for the current financial year, driven by added capacities and new products like PureCoat and UltraMod. - The company has a sustainable revenue growth outlook of 25%-30% annually over the next few years. - MCC segment grew 15%-20%, outpacing the global MCC growth of about 10%, with market share gains from better pricing, service, and a wide product range. - API segment capacity is being expanded from 100 KL to 250 KL, with full utilization expected by mid-FY26. API revenue share is targeted to reach around 30% of total revenue this year. - The CCS and O&M segments are also poised for growth with ongoing and planned capex, contingent on regulatory approvals. - The Gulf operations and Middle East ventures are expected to contribute revenues starting next financial year. - Overall, management is confident of maintaining or improving EBITDA margins alongside revenue growth.

- Sigachi Industries anticipates top-line growth of around 30% for the current financial year, driven by expanded capacities and new product introductions like PureCoat and UltraMod. - EBITDA margins are expected to sustain in the short term, with improvement anticipated over the longer term, particularly as the API segment ramps up post-CEP approvals. - API segment EBITDA margins could reach 20% plus once regulatory approvals (CEP) are in place. - The company is confident of fully utilizing the existing 100 KL capacity before commissioning the additional 150 KL expansion expected by January 2026. - MCC segment utilization is projected to increase to 50% by March 2025, with plans for further capacity addition in the next 2-3 years due to strong demand and market share gains. - Overall revenue growth of 25-30% per annum is expected to continue sustainably over FY25 and FY26. - Margins might temporarily compress due to market penetration pricing but are expected to improve as customer relationships strengthen.

- The company has ongoing efforts to capture markets, especially in regulated markets like the US, Europe, and MENA region, with some opportunities being selectively taken based on risk and sustainability. - CEP approvals, especially for APIs like Propafenone Hydrochloride, are anticipated by Q1 FY26, which will enable better utilization of existing API capacity. - Current API capacity utilization is around 50%, expected to increase as approvals come through and customers start trials. - The firm is confident of full utilization of the current 100 KL API capacity before expanding to 250 KL by January 2025, with the additional capacity becoming operational by January 2026. - Revenue guidance targets about 30% growth year-on-year, supported by multiple capacity expansions and new product launches. - Joint venture activities in Gulf and MENA are ongoing but cautious due to market risk considerations. - Orderbook specifics like exact pending orders are not quantified but expectations are high with multiple CEP filings and regulatory approvals underway.